Announced
Completed
Sofinnova, OMX and Vækstfonden led a $19.5m Series A round in Freya Biosciences.
Financials
Transaction Value£16m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-
Sources
Tags
Denmark
women's health
Health Care Services
Acquisition
Cross Border
Minority
Private
Private Equity
Venture Capital
Completed
Friendly
Synopsis
Sofinnova, a venture capital firm, OMX, a venture capital firm, and Vækstfonden, Denmark's investment fund, led a $19.5m Series A round in Freya Biosciences, a clinical-stage company taking an innovative approach to women's health.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
No credit card required
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.